{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 65,
        "end": 84
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 104,
        "end": 114
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 184,
        "end": 210
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 226,
        "end": 232
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 242,
        "end": 246
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 249,
        "end": 252
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 65,
        "end": 101
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "24598368_5",
  "text": "In 2011 , regulatory entities granted conditional approval to an anaplastic lymphoma kinase inhibitor ( crizotinib ) based on an impressive overall response rate in previously treated non-small cell lung cancer patients whose tumors harbored EML4 / ALK translocations ."
}
